Andra AP fonden Has $736,000 Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Andra AP fonden lessened its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 51.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,200 shares of the biotechnology company's stock after selling 12,000 shares during the period. Andra AP fonden's holdings in BioMarin Pharmaceutical were worth $736,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. TD Private Client Wealth LLC raised its position in BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $36,000. Meeder Asset Management Inc. raised its holdings in shares of BioMarin Pharmaceutical by 920.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 663 shares in the last quarter. True Wealth Design LLC lifted its stake in BioMarin Pharmaceutical by 13,400.0% during the third quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 804 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in BioMarin Pharmaceutical by 111.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock worth $58,000 after buying an additional 466 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

Remove Ads

BioMarin Pharmaceutical Stock Up 0.1 %

Shares of BMRN stock traded up $0.06 on Thursday, hitting $70.60. The company's stock had a trading volume of 931,876 shares, compared to its average volume of 1,773,692. The stock has a market capitalization of $13.47 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 0.61 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The firm's fifty day moving average price is $66.08 and its 200-day moving average price is $69.09. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,344 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. The trade was a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.85% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on BMRN. Citigroup increased their price objective on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Oppenheimer raised BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a research report on Monday, February 24th. Piper Sandler lifted their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research note on Thursday, February 20th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Wolfe Research assumed coverage on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. They issued an "outperform" rating and a $95.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.